(Q30922171)

27 June 2017

0 references

1 reference

title

Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review (English)

1 reference

27 June 2017

0 references

1 reference

1 reference

1 reference

1 reference

S Welch

1

1 reference

27 June 2017

K Spithoff

2

1 reference

27 June 2017

R B Rumble

3

1 reference

27 June 2017

J Maroun

4

1 reference

27 June 2017

Gastrointestinal Cancer Disease Site Group

5

1 reference

27 June 2017

language of work or name

1 reference

25 November 2009

1 reference

27 June 2017

1 reference

27 June 2017

volume

21

1 reference

27 June 2017

issue

6

1 reference

27 June 2017

page(s)

1152-1162

1 reference

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Gastrointestinal perforation due to bevacizumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP533

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP533

1 reference

27 June 2017

1 reference